SU5, a Stable Auraptene Analog, Ameliorates Metabolic Dysfunction-Associated Steatohepatitis Through Modulation of the FXR Signaling Pathway.
Metabolic Dysfunction-Associated Steatohepatitis (MASH), a metabolic liver disease severely threatening public health, is characterized by hepatic steatosis, inflammatory infiltration, and fibrotic progression. Currently, there is still a lack of specific therapeutic approaches for MASH in clinical practice. Auraptene...